BioVentures has released a new podcast episode featuring Dr. Marie Burdine, a member of the most recent AR Health Ventures Accelerator cohort. In the episode, she discusses her team’s research on a drug designed to reduce delayed graft function (DGF), a complication that can occur following kidney transplantation. DGF affects approximately 30% of kidney transplant recipients and is often associated with damage to donor kidneys during transport. Dr. Burdine’s team is evaluating whether adding the drug to organ preservation solutions can reduce injury and improve recovery after transplantation using a preclinical pig transplant model. According to the discussion, early findings indicate faster recovery of kidney function and reduced tissue injury. The research aims to improve transplant outcomes and increase the number of donor organs suitable for transplantation.